Stanislava Macura

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen et al. · The Lancet · 2023 · 297 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Juan P. Frías, Pernille Auerbach, Harpreet S. Bajaj et al. · The Lancet Diabetes & Endocrinology · 2021 · 176 citations

Medicine, Pharmacology, Pharmacotherapy +14

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

Ildiko Lingvay, Thomas K. Hansen, Stanislava Macura et al. · BMJ Open Diabetes Research & Care · 2020 · 78 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes

Edward Franek, Silvija Canecki-Varžić, Stanislava Macura et al. · Diabetic Medicine · 2015 · 51 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Vanita R. Aroda, Matthew Capehorn, Louis Chaykin et al. · Diabetes Obesity and Metabolism · 2019 · 28 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17